ArticleJournal of endocrinological investigation2026
Molecular spectrum of autosomal recessive osteogenesis imperfecta in 93 Italian children with bone fragility: a monocentric experience.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeOsteogenesis imperfecta (OI) usually follows an autosomal dominant inheritance pattern. We aimed to explore the epidemiological impact of autosomal recessive OI in a pediatric population and expand the mutational repertoire in this cohort.
methodsWe presented our six-year (2018–2024) monocentric next-generation sequencing diagnostic activity on 93 unrelated children with a suspicion of OI. Variants were classified according to the American College of Medical Genetics and Genomics recommendations.
results(Likely) pathogenic variants (PLP) or variants of uncertain significance were identified in 61.3% cases (57/93), with conclusive results (i.e. a heterozygous PLP in dominant genes, or biallelic PLP in recessive genes) in 59.1% (55/93). According to age, the rate of conclusive results was 84.0% (21/25), 52.7% (24/46) and 45.4% (10/22) in individuals aged 0–3 years, 4–12 years and 13–16 years, respectively. Six individuals out of 55 (11.0%) with conclusive results had biallelic PLP variants in autosomal recessive genes, among which we found three novel variants in SERPINF1 and WNT1, and confirmed OI as a possible phenotype due to PLOD2 abnormalities.
conclusionsIn our cohort of 93 Italian patients with a suspicion of OI, autosomal recessive OI was epidemiologically significant. Such a diagnostic perspective represents the prerequisite to combine multiprofessional and extended genetic testing assessments in children with OI to improve their diagnosis, management and treatment.
Indexed as
Identifiers
41171600What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.